Top

FOUNDERS

Asset 201.png

Dr Timothy Eviston MBBS PhD FRACS

Chief Executive Officer.


Dr Eviston is a Sydney based surgeon, scientist and entrepreneur. Technology, relationships and innovations underpinning Intravital were developed by Dr Eviston during his PhD studies at UNSW. He is an inventor on a number of patents including Intravital's core technologies.

Dr Eviston specialises in interdisciplinary science, team building and technology integration. From a clinical perspective, Dr Eviston has a special interest in advanced head and neck cancer surgery and reconstruction. In his research capacity Dr Eviston has pioneered techniques and therapies in surgical nerve injury and nerve monitoring. He has presented nationally and internationally and has published in high impact medical and surgical journals. His research collaborations extend across neurobiology, clinical neurophysiology, biomedical engineering and cancer research.

"Intravital's mission is to meaningfully impact the lives of patients. I strongly belive that a future without chronic pain, nerve injury and loss of function after surgery is within our grasp. A patient undergoing surgery should have confidence that they will feel well after their surgery."

Asset 202.png

Prof. Arun Krishnan MBBS PhD FRACP

Chief Medical Officer.


Professor Krishnan is Professor of Medicine at UNSW and is recognised globally as a leader in peripheral nerve injury research. He is a neurologist, clinical neurophysiologist and Head of the Neuromuscular Disease and Multiple Sclerosis Research Group at UNSW. As one of UNSW's youngest full professors, he leads a large research team that has pioneered the development of early biomarkers for peripheral nerve disorders.

Prof Krishnan has extensive experience with running and developing clinical trials and has strong industry ties, working with a number of multinational pharmaceutical and medical device companies globally. He is co-inventor on neuroprotective and nerve injury patents and has been an expert advisor to Industry partners in regulatory matters, both in Australia and internationally. He has published more than 110 academic papers, with many in high impact medical journals.

Asset 203.png
 

Dr Lindsay Wu PhD

Chief Scientific Officer.


Dr Wu is a leading scientist and biotechnology entrepreneur. He is a Cancer Institute NSW Fellow and runs the Laboratory for Ageing Research at UNSW, the partner lab to Harvard's ageing research laboratory. His research focuses on novel compounds and strategies to improve cell survival and function in the face of insults such as old age, chemotherapy, and mechanical stress. He is a founding director of Metro Biotech NSW Pty Ltd and Jumpstart Fertility Pty Ltd and is an inventor on 5 patents.

Dr Wu is a regular speaker at international meetings and is a regular provider of scientific commentary to mainstream media outlets. He recently chaired the Australian Biology of Ageing Conference (ABAC) in Sydney and is recognised as one of the emerging molecular biology experts in the field.

 
Asset 176.png

ADVISORS


Asset 176.png

ADVISORY

BOARD

Professor David Sinclair Harvard University, MA

A member of the TIME 100 "most influential people list", Professor Sinclair is widely known as one of the pioneers of cell survival research. From a scientific perspective he maintains labs at Harvard Medical School as co-director of the Paul F Glenn Laboratories, and at UNSW, Australia. His research focuses on mechanisms of cell survival during old age and stress, such as that encountered during surgical interventions.

Professor Sinclair is also a renowned biotech entrepreneur, having founded or co-founded a number of influential companies including Sirtris (acquired by GlaxoSmithKline for $720M), Genocea Biosciences and Ovascience.

Atul Lele Bridgewater Associates, CT

Atul is well known in the financial industry as one of the leading minds in global macroeconomic issues. Prior to working at Bridgewater, Atul worked as Chief Investment Officer of Deltec International Group, and as Head of Strategy & Economics for Credit Suisse. Within Institutional Equities, he was top ranked by Clients and rated #1 in the Institutional Investor and Peter Lee / Greenwich Surveys over multiple years. Atul is regularly requested to appear in the financial press, including Bloomberg, CNBC, The Wall Street Journal, The New York Times, The Financial Times and numerous other international publications, and has also been featured in a number of investment related books, including “Young Guns on the Share Market” and “Bulls, Bears and a Croupier”.

Andrew Gee Executive Director, Macquarie Bank Limited

Andrew has spent more than 25 years in the financial services industry and has substantial experience in originating significant transactions and growing businesses both domestically and internationally including substantial M&A activity.

Andrew leads the Technology, Media, Telecoms (TMT) division within the Corporate and Asset Finance Group of Macquarie. The TMT division provides specialised financial and asset management solutions to major customers around the world. In addition to leading the TMT team Andrew has developed and closed a number of unique and significant transactions that have led to substantial benefits for Macquarie's customers.

Asset 176.png

SCIENTIFIC

ADVISORY

BOARD

Dr Raj Reddy Prince of Wales Hospital, Sydney, Australia

Dr Reddy is the head of Neurosurgery at Prince of Wales Hospital and a paediatric neurosurgeon at Sydney Children’s Hospital. Dr Reddy has a special interests in paediatric neurosurgery and spine surgery and has completed subspecialist training in complex spine surgery at Toronto Western Hospital and paediatric neurosurgery at The Hospital for Sick Children in Toronto.

Dr Reddy is a professional member of Neurosurgical Society of Australasia, Spine Society of Australasia, American Association of Neurological Surgeons, North American Spine Society, and International Society of Paediatric Neurosurgeons and is passionate about providing high quality evidenced base care and training the next generation of surgeons.

Professor David Morris Professor of Surgery, UNSW

Professor Morris is Professor of Surgery at St George Hospital, Sydney and is widely recognised as one of the most influential surgeons of his generation. As a world leader in surgical oncology and peritoneal cancer, Professor Morris pioneered new treatments for liver cancer, colon cancer, appendiceal cancer and associated conditions. He has published more than 800 peer reviewed articles, has maintained a science and oncology lab for more than 20 years and has an extensive track record of commercialising pharma and medical devices from concept to market including through trade sale, licensing and IPO. Professor Morris has profoundly impacted a number of fields during his distinguished career. He invented the first effective medication for Hydatid disease, a common parasitic disease, and has developed profoundly new surgical techniques for treating liver cancers. One of his most influential developments has been the reduction in mortality associated with advanced abdominal cancer surgery, a legacy which will survive amongst the generations of surgeons he has trained.